Noopept Powder

(No reviews yet) Write a Review


Notice: This product is sold as a cognitive compound used for research purposes only. Any usage is based on your own research, please consider all warnings and recommendations before completing purchase. By purchasing this product, you agree to potential risks associated with this particular ingredients and our terms & conditions.

Ingredient List:
 Noopept Powder

The molecule N-phenylacetyl-L-prolylglycine ethyl ester is commonly referred to as 'Noopept', and is a synthetic molecule commonly said to be in the racetam class (although this is technically not true, due to Noopept not having a 2-oxo-pyrollidine nucleus). It was synthesized in 1996[2] and was based off of the endogenous neuropeptide cycloprolylglycine[2][3] and is said to be anxiolytic and mildly psychostimulatory while promoting cognitive health and memory.[4]

It is commonly said to be 1000-fold as potent as piracetam (derived from the abstract of a German review[5]) although elsewhere it has been claimed to be more variable, at somewhere between 200 and 50,000 when comparing the two molecules on a dose-per-dose basis.[6] On a structural basis, Noopept is a dipeptide conjugate of Piracetam.[1]


Study: Synthesis and antiamnesic activity of a series of N-acylprolyl-containing dipeptides[2]
Abstract - These N-acylprolyl-containing dipeptides were designed as analogues of pyroglutamyl-containing dipeptides, which we previously demonstrated to be highly active nootropics. Among the structure—activity relationships explored were the effect of N-acyl-substitution size.[2]

Study: Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test.[3]
Abstract - Testing in an elevated plus-maze revealed dose-dependent anxiolytic activity of piracetam analog cycloprolylglycine. Intraperitoneal injection of this agent (0.05 mg/kg) 9-fold prolonged the time spent in open arms compared to the control, without affecting the total motor activity. This effect was stereo-selective: D-enantiomer in doses of 0.05 and 0.1 mg/kg was inactive. Therefore, cycloprolylglycine is similar to piracetam in not only nootropic, but also anxiolytic activity. The existence of an endogenous system responsible for the co-regulation of memory and anxiety is hypothesized.[3]

Study: The original novel nootropic and neuroprotective agent noopept[5]
Abstract - The paper describes pharmacological properties of the new nootropic drug noopept created using an original approach based on the imitation of a nonpeptide nootrope structure by means of the short-peptide design. In particular, the structure of pyracetam was designed using dipeptide nootropes. Experimental investigations of noopept (N-phenylacetyl-L-polyglycine ethyl ester) showed that the new drug exceeds pyracetam both with respect to the effective dose level (1000 times lower for noopept than for pyracetam) and in the spectrum of mnemotropic activity. In contrast to pyracetam facilitating only the early stages of the memory process, noopept positively influences the memory consolidation and retrieval steps as well. The new drug produces an additional selective anxiolytic action. The pronounced neuroprotective effect of noopept was demonstrated both in vivo (in cases of various forms of brain ischemia) and in vitro (on various neuronal models). The drug action is based on the antioxidant effect, the antiinflammatory action, and the ability to inhibit the neurotoxicity of excess calcium and glutamate, and to improve the blood rheology. It was established for the first time that the activity of noopept is retained both upon parenteral introduction and upon peroral administration, which is a principal advantage of this proline-containing dipeptide over other, more complex peptides. This property provided a basis for the development of a medicinal form of noopept for peroral usage. At present, noopept tablets (noopept 5 and 10 mg) are under clinical assessment as a means of treating cognitive deficiency of cerebrovascular and post-traumatic origin.[5]

Study: Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity.[6]
Abstract - Parkinson's disease is a common neurodegenerative disorder characterized by α-synuclein (α-Syn)-containing Lewy body formation and selective loss of dopaminergic neurons in the substantia nigra. We have demonstrated the modulating effect of noopept, a novel proline-containing dipeptide drug with nootropic and neuroprotective properties, on α-Syn oligomerization and fibrillation by using thioflavin T fluorescence, far-UV CD, and atomic force microscopy techniques. Noopept does not bind to a sterically specific site in the α-Syn molecule as revealed by heteronuclear two-dimensional NMR analysis, but due to hydrophobic interactions with toxic amyloid oligomers, it prompts their rapid sequestration into larger fibrillar amyloid aggregates. Consequently, this process rescues the cytotoxic effect of amyloid oligomers on neuroblastoma SH-SY5Y cells as demonstrated by using cell viability assays and fluorescent staining of apoptotic and necrotic cells and by assessing the level of intracellular oxidative stress. The mitigating effect of noopept against amyloid oligomeric cytotoxicity may offer additional benefits to the already well-established therapeutic functions of this new pharmaceutical.[6]

Citation & Resources:






These statements have not been evaluated by the Food & Drug Administration. This product is not approved by the FDA. This product is not intended to diagnose, treat, cure or prevent any diseases.

Keep out of the reach of children. Do not take this or any other compound if under the age of 18, pregnant or nursing a baby, or if you have any known or suspected medical conditions and/or taking prescription drug(s) or OTC medication(s). Always consult with a qualified health physician before taking any new compound.

View AllClose

0 Reviews

View AllClose